1. Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol. Jan 15 2003;41(2):263-272.
2. Bramlet DA, King H, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. Am J Cardiol. Oct 30 1997;80(8B):39H-44H.
3. Maviglia SM, Teich JM, Fiskio J, Bates DW. Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. J Gen Intern Med. Aug 2001;16(8):531-537.
4. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National Trends in Statin Use by Coronary Heart Disease Risk Category. PLoS Medicine. May 1, 2005 2005;2(5):e123.
5. Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Arch Intern Med. Feb 14 2000;160(3):343-347.
6. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. Feb 19 1996;164(4):208-211.
7. The Top 200 Presciptions for 2003 by Number of US Presciptions Dispensed. NDC Health. Available at: http://www.rxlist.com/top200.htm. Accessed January 14, 2005, 2005.
8. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of Statin Therapy in Adults With Coronary Heart Disease. Arch Intern Med. July 12, 2004 2004;164(13):1427-1436.
9. Edwards J, Moore RA. Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Family Practice. 2003;4(1):18.
10. Walsh JME, Pignone M. Drug Treatment of Hyperlipidemia in Women. JAMA. May 12, 2004 2004;291(18):2243-2252.
11. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. October 21, 2000 2000;321(7267):983-986.
12. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. Apr 5 2003;361(9364):1149-1158.
13. Hague W, Forder P, Simes J, Hunt D, Tonkin A. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am Heart J. Apr 2003;145(4):643-651.
14. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. Mar 6 2004;363(9411):757-767.
15. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. June 25, 2003 2003;326(7404):1423-.
16. The Stroke Council. Statins After Ischemic Stroke and Transient Ischemic Attack: An Advisory Statement From the Stroke Council, American Heart Association and American Stroke Association. Stroke. April 1, 2004 2004;35(4):1023-.
17. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. Aug 21 2004;364(9435):685-696.
18. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. Jun 14 2003;361(9374):2005-2016.
19. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. July 13, 2004 2004;110(2):227-239.
20. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. Dec 3 1999;286(5446):1946-1949.
21. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA Reductase Inhibitors and the Risk of Fractures. JAMA. June 28, 2000 2000;283(24):3205-3210.
22. van Staa T-P, Wegman S, de Vries F, Leufkens B, Cooper C. Use of Statins and Risk of Fractures. JAMA. April 11, 2001 2001;285(14):1850-1855.
23. Bauer DC, Mundy GR, Jamal SA, et al. Use of Statins and Fracture: Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials. Arch Intern Med. January 26, 2004 2004;164(2):146-152.
24. Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet. Feb 17 2001;357(9255):509-512.
25. Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group. Jama. Oct 18 2000;284(15):1921-1922.
26. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. Jul 15 2003;92(2):152-160.
27. Mele J. Crestor (ZD4522, rosuvastatin calcium) tablets: Comments on Efficacy. Available at: http://www.fda.gov/ohrms/dockets/ac/03/slides/3968S1_02_FDA-Mele.ppt#8. Accessed January 13, 2005.
28. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med. April 8, 2004 2004;350(15):1495-1504.
29. de Lemos JA, Blazing MA, Wiviott SD, et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial. JAMA. September 15, 2004 2004;292(11):1307-1316.
30. LaRosa JC, Grundy SM, Waters DD, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med. April 7, 2005 2005;352(14):1425-1435.
31. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. Mar 1 1998;81(5):582-587.
32. Pitt B. Low-Density Lipoprotein Cholesterol in Patients with Stable Coronary Heart Disease -- Is It Time to Shift Our Goals? N Engl J Med. March 8, 2005 2005:NEJMe058052.
33. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial. JAMA. March 3, 2004 2004;291(9):1071-1080.
34. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol. Aug 1 2001;88(3):291-293.
35. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N Engl J Med. January 6, 2005 2005;352(1):29-38.
36. Ridker PM, Cannon CP, Morrow D, et al. C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med. January 6, 2005 2005;352(1):20-28.
37. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein. Circulation. July 20, 1999 1999;100(3):230-235.
38. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of Statin Therapy on C-Reactive Protein Levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A Randomized Trial and Cohort Study. JAMA. July 4, 2001 2001;286(1):64-70.
39. Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*. Circulation. November 11, 2003 2003;108(19):2292-2297.
40. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. Jul-Aug 2001;35(7-8):908-917.
41. Staffa JA, Chang J, Green L. Cerivastatin and Reports of Fatal Rhabdomyolysis. N Engl J Med. February 14, 2002 2002;346(7):539-a-540.
42. Docket No. 2004P-0113/CP1. FDA. Available at: http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf. Accessed March, 2005.
43. Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet. Jun 26 2004;363(9427):2189-2190.
44. FDA. Public Health Advisory for Crestor (rosuvastatin). Available at: http://www.fda.gov/cder/drug/advisory/crestor.htm. Accessed January 13, 2005.
45. Pasternak RC, Smith SC, Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation. August 20, 2002 2002;106(8):1024-1028.
46. Swan GE, LaRue A, Carmelli D, Reed TE, Fabsitz RR. Decline in cognitive performance in aging twins. Heritability and biobehavioral predictors from the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol. May 1992;49(5):476-481.
47. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. Nov 11 2000;356(9242):1627-1631.
48. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. Mar 2002;59(3):378-384.
49. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. Jul 2003;23(7):871-880.
50. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. May 2000;108(7):538-546.
51. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. Dec 1 2004;117(11):823-829.
52. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased Prevalence of Alzheimer Disease Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors. Arch Neurol. October 1, 2000 2000;57(10):1439-1443.
53. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. Feb 2005;62(2):217-224.
54. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. Nov 23 2002;360(9346):1623-1630.
55. Golomb BA, Criqui MH, White H, Dimsdale JE. Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry. Arch Intern Med. January 26, 2004 2004;164(2):153-162.
56. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Bmj. Feb 15 1992;304(6824):431-434.
57. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. Jul 1998;32(1):140-146.
58. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. Jul 6 2002;360(9326):7-22.
59. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. July 23, 1997 1997;278(4):313-321.
60. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. Jun 15 2001;110(9):716-723.
61. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. Aug 28 2004;364(9436):771-777.
62. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the Risk of Colorectal Cancer. N Engl J Med. May 26, 2005 2005;352(21):2184-2192.
63. SoRelle R. Cardiovascular News. Circulation. December 5, 2000 2000;102(23):9044e-9045.
64. FDA Warns Consumers to Avoid Red Yeast Rice Products Promoted on Internet as Treatments for High Cholesterol: Products found to contain unauthorized drug. U.S. Food and Drug Administration. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01678.html. Accessed August 9, 2007.
65. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VLW. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. February 1, 1999 1999;69(2):231-236.
66. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. Apr 2001;7(2):133-139.
67. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. Sep 13 1999;159(16):1893-1900.
68. Hunninghake DB, Stein EA, Bremner WF, Greenland P, Demke DM, Oliphant TH. Dose--Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia. Am J Ther. Mar 1995;2(3):180-189.
69. Superko HR, Greenland P, Manchester RA, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol. Jul 15 1992;70(2):135-140.
70. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. Jama. Jan 20 1984;251(3):351-364.
71. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Jama. Jan 20 1984;251(3):365-374.
72. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. Dec 17 2002;106(25):3143-3421.
73. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. Apr 11 2005;165(7):725-730.
74. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. Jun 2001;24(6):467-474.
75. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. Apr 1 2001;110(5):352-360.
76. Kornitzer M, Dramaix M, Vandenbroek MD, Everaert L, Gerlinger C. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis. Oct 1994;110 Suppl:S49-54.
77. Brown WV, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis. Nov-Dec 1986;6(6):670-678.
78. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. Jama. Dec 8 1989;262(22):3154-3160.
79. Pauciullo P, Marotta G, Rubba P, et al. Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia. J Intern Med. Nov 1990;228(5):425-430.
80. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. Oct 7 1997;96(7):2137-2143.
81. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. Mar 24 2001;357(9260):905-910.
82. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. Oct 1978;40(10):1069-1118.
83. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. Nov 12 1987;317(20):1237-1245.
84. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. Aug 5 1999;341(6):410-418.
85. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223(5):405-418.
86. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. May 2005;26(9):897-905.
87. Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol. Dec 2000;56(9-10):631-635.
88. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. Feb 15 2005;95(4):462-468.
89. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. Sep 1 1997;80(5):608-613.
90. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. May 17 2005;45(10):1649-1653.
91. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther. Oct 2004;26(10):1599-1607.
92. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. Jul 1999;138(1 Pt 1):151-155.
93. Shek A, Ferrill M. Statin-fibrate combination therapy. Ann Pharmacother. July 1, 2001 2001;35(7):908-917.
94. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. Oct 1 2004;94(7):935-938.
95. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. Jan 1 2005;95(1):120-122.
96. Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci. Mar 2001;46(3):540-544.
97. Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. N Engl J Med. May 26 1977;296(21):1185-1190.
98. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. Aug 2000;68(2):122-129.
99. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. May 2004;75(5):455-463.
100. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. Dec 2002;72(6):685-691.
101. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. May 2001;69(5):340-345.
102. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. Jun 2003;73(6):538-544.
103. Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. Mar 2000;40(3):316-323.
104. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. Feb 2003;25(2):459-471.
105. Corbelli JC, Bullano MF, Willey VJ, Cziraky MJ, Corbelli ME, Waugh W. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. Am J Cardiol. Dec 15 2002;90(12):1388-1391.
106. Packard KA, Backes JM, Lenz TL, Wurdeman RL, Destache C, Hilleman DE. Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy. Dec 2002;22(12):1527-1532.
107. Insua A, Massari F, Rodriguez Moncalvo JJ, Ruben Zanchetta J, Insua AM. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract. Mar-Apr 2002;8(2):96-101.
108. Malik S, Kashyap ML. Niacin, lipids, and heart disease. Curr Cardiol Rep. Nov 2003;5(6):470-476.
109. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. Jan 1981;22(1):24-36.
110. Guyton JR, Blazing MA, Hagar J, et al. Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol. Arch Intern Med. April 24, 2000 2000;160(8):1177-1184.
111. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. Sep 15 1998;82(6):737-743.
112. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med. Nov 1988;148(11):2493-2495.
113. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. Jul 25 1994;154(14):1586-1595.
114. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. Jama. Mar 2 1994;271(9):672-677.
115. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. Sep 1998;47(9):1097-1104.
116. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. Dec 17 1998;82(12A):74U-81U; discussion 85U-86U.
117. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. Jul 1985;34(7):642-650.
118. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol. Dec 17 1998;82(12A):35U-38U; discussion 39U-41U.
119. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. Jan 10 1994;154(1):73-82.
120. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med. Jun 6 1994;96(6A):64S-68S.
121. Goldberg AC. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol. Jul 1 2004;94(1):121-124.
122. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. Aug 1 2001;88(3):270-274.
123. Clofibrate and Niacin in Coronary Heart Disease. JAMA. 1975;231:360-381.
124. Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. Feb 15 2001;87(4):476-479, A477.
125. Stein EA, Davidson MH, Dujovne CA, et al. Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial. J Cardiovasc Pharmacol Ther. Apr 1996;1(2):107-116.
126. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. Mar 15 2003;91(6):667-672.
127. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. Jun 1 2003;91(11):1304-1310.
128. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. Mar 15 2002;89(6):672-678.
129. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. Nov 29 2001;345(22):1583-1592.
130. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. Nov 8 1990;323(19):1289-1298.
131. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Jama. Jun 19 1987;257(23):3233-3240.
132. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. Jan 18 2005;142(2):95-104.
133. McKenney J. New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders. Arch Intern Med. April 12, 2004 2004;164(7):697-705.
134. Knopp RH. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am J Cardiol. Dec 17 1998;82(12A):24U-28U; discussion 39U-41U.
135. Goldberg A, Alagona P, Jr., Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. May 1 2000;85(9):1100-1105.
136. Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol. Mar 15 1998;81(6):805-807.
137. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. Jan 1992;92(1):77-81.
138. Hodis HN. Acute hepatic failure associated with the use of low-dose sustained-release niacin. Jama. Jul 11 1990;264(2):181.
139. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med. Aug 1 1989;111(3):253-255.
140. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non- insulin-dependent diabetes mellitus. Jama. Aug 8 1990;264(6):723-726.
141. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. Jama. Sep 13 2000;284(10):1263-1270.
142. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes: Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. July 22, 2002 2002;162(14):1568-1576.
143. Zetia (ezetimibe) tablets. Merck/Schering-Plough Pharmaceuticals. August 2004. Available at: http://www.zetia.com/zetia/shared/documents/zetia_pi.pdf, 2004.
144. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. Apr 2003;24(8):729-741.
145. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. Nov 15 2002;90(10):1092-1097.
146. Sudhop T. Inhibition of Cholesterol Absorption by Ezetimibe -- A New Approach in Lowering Cholesterol. Cardiovasc Rev Rep. 2004;25(5):225-228.
147. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. Feb 15 2003;91(4):418-424.
148. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. Apr 2003;24(8):717-728.
149. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. Dec 18 2002;40(12):2125-2134.
150. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial. Circulation. May 20, 2003 2003;107(19):2409-2415.